Compare ACOG & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACOG | TNXP |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | Canada | United States |
| Employees | 71 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.1M | 199.7M |
| IPO Year | N/A | 2008 |
| Metric | ACOG | TNXP |
|---|---|---|
| Price | $8.52 | $11.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | 100.6K | ★ 505.8K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $139.22 | $558.11 |
| Revenue Next Year | $134.48 | $38.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $4.50 | $9.40 |
| 52 Week High | $10.10 | $69.65 |
| Indicator | ACOG | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 50.95 |
| Support Level | $5.27 | $10.03 |
| Resistance Level | $9.04 | $13.18 |
| Average True Range (ATR) | 0.86 | 0.80 |
| MACD | -0.05 | 0.09 |
| Stochastic Oscillator | 46.33 | 56.48 |
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.